Amerikanische Gesellschaft für Hirudotherapie

Cardiopulmonary bypass in humans: bypassing unfractionated heparin.

Review published in The Annals of thoracic surgery (2000)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienArzneimittelentwicklungFrederiksen · The Annals of thoracic surgery, 2000

Abstract

Seven anticoagulants besides unfractionated heparin have been used for human cardiopulmonary bypass (CPB), mainly in patients with heparin-induced thrombocytopenia. The collective experience with these alternative anticoagulants provides a perspective on current efforts aimed at improving CPB anticoagulation. Unfortunately, each alternative currently lacks a standard dosing schedule and a reliable method of monitoring the adequacy of its anticoagulant effect during CPB. Most also lack proven antidotes. Thus, unfractionated heparin remains the anticoagulant of choice for standard CPB.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsCardiopulmonary BypassDose-Response Relationship, DrugDrug Administration ScheduleHeparinHumansThrombocytopenia

Zusammenfassung

Seven anticoagulants besides unfractionated heparin have been used for human cardiopulmonary bypass (CPB), mainly in patients with heparin-induced thrombocytopenia. The collective experience with these alternative anticoagulants provides a perspective on current efforts aimed at improving CPB anticoagulation.

Warum dies für die Hirudotherapie relevant ist

This review discusses seven anticoagulants used as alternatives to unfractionated heparin during human cardiopulmonary bypass, primarily in patients with heparin-induced thrombocytopenia. The authors note that each alternative currently lacks a standard dosing schedule, a reliable monitoring method for anticoagulant adequacy during bypass, and, in most cases, a proven antidote, leaving unfractionated heparin as the anticoagulant of choice for standard cardiopulmonary bypass. The abstract does not mention leeches, hirudin, hirudotherapy, or any leech-derived molecules. The article's connection to the American Society of Hirudotherapy is therefore nonexistent based on the abstract alone, as it focuses entirely on conventional anticoagulant alternatives for surgical bypass.

Zitation

Cardiopulmonary bypass in humans: bypassing unfractionated heparin.

Frederiksen · The Annals of thoracic surgery, 2000

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Clinical EvidenceClinical ApplicationsDrug PipelineDrug DevelopmentDirect Thrombin InhibitorsMicrosurgery OutcomesSurgeryAnticoagulation CompoundsHemostasisOtolaryngologyPulmonology

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.